Appendix 2: Anticoagulant options for initial management of iliofemoral deep vein thrombosis	
Treatment	Suggested dosing regimen
Unfractionated	SC administration: 333 IU/kg bolus, followed by 250 IU/kg SC twice daily
heparin ^{1,2}	IV administration: 80 IU/kg bolus, followed by 18 IU/kg per hour infusion
Low-molecular-	Dalteparin: 200 IU/kg SC once daily
weight heparin ³	Enoxaparin: 1.5 mg/kg SC once daily or 1 mg/kg SC twice daily
	Tinzaparin: 175 IU/kg SC once daily
	Nadroparin: 171 IU/kg SC once daily
Fondaparinux ¹	Body weight < 50 kg: 5 mg SC daily
	Body weight 50–100 kg: 7.5 mg SC daily
	Body weight > 100 kg: 10 mg SC daily
Rivaroxaban*4,5	15 mg PO twice daily for 21 days, then 20 mg PO once daily
Apixaban*6	10 mg twice daily for 7 days, followed by 5 mg twice daily
•	

Note: IV = intravenous, PO = by mouth (orally), SC = subcutaneous.

References

- Garcia DA, Baglin TP, Weitz JI, et al. Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines [published errata: Chest 2012;141:1369 and Chest 2013;144:721]. Chest 2012;141(2 Suppl):e24S-e43S.
- 2. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012;141(2 Suppl):e152S-e184S.
- 3. Thomson P, Brocklebank C, Semchuk W. Treatment dosing of low-molecular weight heparins and the dose cap dilemma: considerations for patients in Canada. *Can J Hosp Pharm* 2009;62:367-74.
- 4. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. *N Engl J Med* 2010;363:2499-510.
- 5. Büller HR, Prins MH, Lensin AW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. *N Engl J Med* 2012;366:1287-97.
- 6. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med* 2013;369:799-808.

^{*}Rivaroxaban and apixaban should not be used for initial treatment of iliofemoral DVT in patients with cancer.